ILDONG HOLDINGS CO.,LTD
Financials
Valuation Metrics
ILDONG HOLDINGS CO.,LTD's Market Cap is ₩733B. At end of 2025 it was ₩1534B. Ranked #1454 of 2,436 in KR market (top 60%), #629 of 787 on KOSPI (top 80%), #161 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 69%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 73.28B KRW | KR#1,454/2,436 Sec#161/234 |
| Revenue | 590.01B KRW | KR#558/2,436 Sec#25/234 |
| Net Income | 32.57B KRW | KR#484/2,436 Sec#32/234 |
| Total Assets | 793.19B KRW | KR#540/2,436 Sec#31/234 |
| Net Assets | 347.83B KRW | KR#640/2,436 Sec#41/234 |
| Employees | 84 | KR#1,763/2,436 Sec#142/234 |
| Value | ||
| P/E | 2.25x | KR#66/2,436 Sec#3/234 |
| P/B | 0.21x | KR#131/2,436 Sec#3/234 |
| P/S | 0.12x | KR#184/2,436 Sec#1/234 |
| EV/EBITDA | 11.71x | KR#700/2,436 Sec#37/234 |
| FCF Yield | 17.51% | KR#389/2,436 Sec#7/234 |
| Profitability | ||
| ROE | 9.36% | KR#561/2,436 Sec#34/234 |
| ROA | 4.11% | KR#771/2,436 Sec#66/234 |
| Op. Margin | 3.34% | KR#1,152/2,436 Sec#90/234 |
| Revenue Growth | -0.59% | KR#1,477/2,436 Sec#142/234 |
| Earnings Growth | -71.57% | KR#1,281/2,436 Sec#85/234 |
| Financial Health | ||
| Debt Ratio | 228.04% | KR#1,888/2,436 Sec#204/234 |
| Total Debt | 211.25B KRW | KR#477/2,436 Sec#25/234 |
| FCF | 12.83B KRW | KR#641/2,436 Sec#36/234 |
| Cash | 53.46B KRW | KR#722/2,436 Sec#44/234 |
| Current Ratio | 0.80x | KR#2,035/2,436 Sec#195/234 |
| Net Debt/EBITDA | 8.00x | KR#1,224/2,436 Sec#89/234 |
| Dividend | ||
| Div. Yield | 1.62% | KR#992/2,436 Sec#54/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -23.49% | KR#1,376/2,436 Sec#117/234 |
| 1M Return | -0.63% | KR#949/2,436 Sec#88/234 |
| From 52W High | -63.02% | KR#1,863/2,436 Sec#157/234 |
| 1Y MDD | -64.20% | KR#1,657/2,436 Sec#137/234 |
| Trading | ||
| Volume | 15,794 shares | KR#1,959/2,436 Sec#195/234 |
| Foreign Own. | 2.64% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | 1,482 KRW | KR#477/2,436 Sec#32/234 |
| BPS | 14,823 KRW | KR#663/2,436 Sec#45/234 |
Company Info
Established in 1941, this company transitioned to a holding company structure in 2016, with Ildong Pharmaceutical and UNIQPLAN as its main subsidiaries. Its subsidiaries engage in diverse businesses such as pharmaceutical manufacturing and sales, advertising agency services, and software development, generating profits through investments and other activities. The company is strengthening its competitiveness by establishing a fast and professional decision-making system and pursuing the dispersion of management risks by concentrating corporate capabilities. Ildong Holdings was founded in 1941 and is headquartered in Seocho-gu, Seoul.